Possible Reactivation of Potential Hepatitis B Virus Occult Infection by Tumor Necrosis Factor-alpha Blocker in the Treatment of Rheumatic Diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yun Jung | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Sung, Yoon-Kyoung | - |
dc.contributor.author | Kim, Tae-Hwan | - |
dc.contributor.author | Jun, Jae-Bum | - |
dc.contributor.author | Yoo, Dae-Hyun | - |
dc.contributor.author | Kim, Tae Yeob | - |
dc.contributor.author | Sohn, Joo Hyun | - |
dc.contributor.author | Lee, Hye-Soon | - |
dc.date.accessioned | 2022-12-20T19:12:39Z | - |
dc.date.available | 2022-12-20T19:12:39Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2010-02 | - |
dc.identifier.issn | 0315-162X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175527 | - |
dc.description.abstract | Objective. To assess the safety of anti-tumor necrosis factor (TNF-alpha) therapy in patients with rheumatic diseases in terms of the reactivation of potential hepatitis B virus (HBV) occult infection. Methods. Patients who had taken anti-TNF-alpha, for the treatment of rheumatic diseases from January 2002 to May 2008 were included in the study. In this patient croup, we retrospectively investigated a series of serum aminotransferase levels. HBV serologic status. the type of anti-TNF-alpha therapy. duration of the anti-TNF-alpha, treatment, and Concurrent use of hepatotoxic drugs. Results. A total of 266 cases were documented using 3 serologic markers for HBV infection: HBV surface antigen (HBsAg). HBV surface antibody (HBsAb). and HBV core IgG Ab (HBcAb). Of these, 8 cases had chronic hepatitis B (HBsAg+). 170 cases were HBcAb-negative, and 88 cases were identified as having potential HBV occult infections represented by HBsAg-negative and HBcAb-positive irrespective of the status of the HBsAb. The frequency of clinically significant (>2 times normal value) and persistent increase (>2 consecutive tests) of aminotransferase levels was significantly higher in the group with a potential HBV occult infection compared to the HBcAb-negative group. In the Multiple logistic regression analysis controlling for various potential confounding factors such as prophylactic anti-tuberculosis medication, methotrexate. nonsteroidal antiinflammatory drugs, and the type of anti-TNF-alpha therapy, only potential HBV occult infection was a significant risk factor for abnormal liver function test (LFT). Conclusion. All rheumatic patients who plan to take anti-TNF-alpha treatment should undergo a test for serology, including HBcAb, and have a Close followup with an LFT test during. therapy. Further prospective studies for hepatitis B viral loud using HBV-polymerase chain reaction in patients who are HbcAb positive are needed to identify whether the abnormal LFT comes from the reactivation of occult HBV infection. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | J RHEUMATOL PUBL CO | - |
dc.title | Possible Reactivation of Potential Hepatitis B Virus Occult Infection by Tumor Necrosis Factor-alpha Blocker in the Treatment of Rheumatic Diseases | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.contributor.affiliatedAuthor | Sung, Yoon-Kyoung | - |
dc.contributor.affiliatedAuthor | Kim, Tae-Hwan | - |
dc.contributor.affiliatedAuthor | Jun, Jae-Bum | - |
dc.contributor.affiliatedAuthor | Yoo, Dae-Hyun | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyun | - |
dc.contributor.affiliatedAuthor | Lee, Hye-Soon | - |
dc.identifier.doi | 10.3899/jrheum.090436 | - |
dc.identifier.scopusid | 2-s2.0-76649143366 | - |
dc.identifier.wosid | 000274498500019 | - |
dc.identifier.bibliographicCitation | JOURNAL OF RHEUMATOLOGY, v.37, no.2, pp.346 - 350 | - |
dc.relation.isPartOf | JOURNAL OF RHEUMATOLOGY | - |
dc.citation.title | JOURNAL OF RHEUMATOLOGY | - |
dc.citation.volume | 37 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 346 | - |
dc.citation.endPage | 350 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | HBV REACTIVATION | - |
dc.subject.keywordPlus | IMMUNE-RESPONSE | - |
dc.subject.keywordPlus | SURFACE-ANTIGEN | - |
dc.subject.keywordPlus | HCV INFECTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | ARTHRITIS | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | ANTIBODIES | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordAuthor | TUMOR NECROSIS FACTOR-alpha BLOCKER | - |
dc.subject.keywordAuthor | HEPATITIS B VIRUS | - |
dc.subject.keywordAuthor | OCCULT INFECTION | - |
dc.subject.keywordAuthor | RHEUMATIC DISEASES | - |
dc.identifier.url | https://www.jrheum.org/content/37/2/346 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.